Clinical Trial Update: Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of Rebamipide 2% ophthalmic suspension for dry eye disease and keratoconjunctivitis sicca. The study has been compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• Rebamipide 2% ophthalmic suspension (rebamipide)

Snippet

Sponsor: Kubota Vision Inc. | Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED